Multicenter phase II study of adding bi-weekly cetuximab to oral S-1 therapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies

Trial Profile

Multicenter phase II study of adding bi-weekly cetuximab to oral S-1 therapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2011 Planned End Date added to 1 Sep 2016 as reported by University Hospital Medical Information Network - Japan.
    • 13 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top